Pacer Advisors Inc. Has $778,000 Stock Position in Haemonetics Co. (NYSE:HAE)

Pacer Advisors Inc. lifted its position in shares of Haemonetics Co. (NYSE:HAEFree Report) by 64.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,098 shares of the medical instruments supplier’s stock after purchasing an additional 3,579 shares during the quarter. Pacer Advisors Inc.’s holdings in Haemonetics were worth $778,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Carmel Capital Partners LLC acquired a new stake in shares of Haemonetics during the 3rd quarter worth approximately $30,000. Meeder Asset Management Inc. grew its holdings in shares of Haemonetics by 65.2% during the 4th quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 135 shares in the last quarter. State of Wyoming acquired a new stake in shares of Haemonetics during the 4th quarter worth approximately $28,000. AdvisorNet Financial Inc grew its holdings in shares of Haemonetics by 3,963.6% during the 3rd quarter. AdvisorNet Financial Inc now owns 447 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 436 shares in the last quarter. Finally, Belpointe Asset Management LLC grew its holdings in shares of Haemonetics by 65.5% during the 1st quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 180 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

Haemonetics stock opened at $83.91 on Thursday. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The company has a market capitalization of $4.26 billion, a PE ratio of 34.11, a price-to-earnings-growth ratio of 2.00 and a beta of 0.36. Haemonetics Co. has a one year low of $70.74 and a one year high of $95.26. The business has a 50 day simple moving average of $77.29 and a 200 day simple moving average of $83.11.

Haemonetics (NYSE:HAEGet Free Report) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.94 by $0.10. The business had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. Haemonetics’s revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the company earned $0.85 EPS. On average, sell-side analysts forecast that Haemonetics Co. will post 3.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Finally, Barrington Research restated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a research report on Tuesday, February 13th.

Check Out Our Latest Research Report on HAE

Haemonetics Profile

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Featured Stories

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEFree Report).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.